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Abstract
Background:  A prospective single-center study was performed to study infection with
lymphotropic herpesviruses (LH) Epstein-Barr virus (EBV), cytomegalovirus (CMV) and human
herpesvirus 6 (HHV-6) in children with cancer.
Methods: The group of 186 children was examined for the presence of LH before, during and 2
months after the end of anticancer treatment. Serology of EBV and CMV was monitored in all
children, serology of HHV-6 and DNA analysis of all three LH was monitored in 70 children.
Results: At the time of cancer diagnosis (pre-treatment), there was no difference between cancer
patients and age-matched healthy controls in overall IgG seropositivity for EBV (68.8% vs. 72.0%; p
= 0.47) and CMV (37.6% vs. 41.7%; p = 0.36). During anticancer therapy, primary or reactivated
EBV and CMV infection was present in 65 (34.9%) and 66 (35.4%) of 186 patients, respectively,
leading to increased overall post-treatment IgG seropositivity that was significantly different from
controls for EBV (86.6% vs. 72.0%; p = 0.0004) and CMV (67.7% vs. 41.7%; p < 0.0001). Overall
pre-treatment IgG seropositivity for HHV-6 was significantly lower in patients than in controls
(80.6% vs. 91.3%; p = 0.0231) which may be in agreement with Greaves hypothesis of protective
effect of common infections in infancy to cancer development. Primary or reactivated HHV-6
infection was present in 23 (32.9%) of 70 patients during anticancer therapy leading to post-
treatment IgG seropositivity that was not significantly different from controls (94.3% vs. 91.3%; p
= 0.58). The LH infection occurred independently from leukodepleted blood transfusions given.
Combination of serology and DNA analysis in detection of symptomatic EBV or CMV infection was
superior to serology alone.
Conclusion: EBV, CMV and HHV-6 infections are frequently present during therapy of pediatric
malignancy.
Background
Extensive bone marrow infiltration with cancer cells and
anticancer therapy lead to immune incompetence in chil-
dren with cancer [1,2]. Since the prognosis and overall
survival of children with cancer have dramatically im-
proved during past 30 years [3], problems remain related
to infections, mainly during leukopenic periods [3–5].
Causal pathogens of febrile neutropenia (FN), most fre-
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quently bacterial or fungal, are identified and confirmed
by culture in 25–35% of the cases [3,6]. In other 15–25%
of patients with FN, bacterial or fungal pathogens are sus-
pected clinically. The remaining 50% of cases are classi-
fied as a fever of unknown origin (FUO) and may be
caused by other pathogens, namely viruses, that are more
difficult to detect by conventional diagnostic methods [7–
9].
Lymphotropic herpesviruses (LH) Epstein-Barr virus
(EBV), cytomegalovirus (CMV) and human herpesvirus-6
(HHV-6) establish a lifelong persistent infection in a great
majority of humans. They usually produce inaparent in-
fection or transient immune compromise in otherwise
healthy hosts but are able to cause life-threatening prima-
ry or reactivated infections in individuals with congenital
or acquired T-cell immunodeficiencies [7–15]. The spec-
trum of diseases caused by lymphotropic herpesviruses is
well documented in patients undergoing bone marrow
transplantation (BMT) [8–11] or organ transplantation
[12,13] and in individuals infected with human immuno-
deficiency virus (HIV) [14,15]. In patients undergoing
conventional anticancer therapy without BMT, the data
focusing on EBV, CMV or HHV-6 infection are scarcely
documented and mostly reported as individual cases [16–
19]. With combined diagnostic approach of serology and
viral DNA detection we performed a prospective study of
children undergoing non-BMT therapy for cancer to dem-
ostrate the incidence of LH infections.
Methods
Patients and controls
Two hundred and nine Caucasian children and adoles-
cents 4 months to 17 years old at the time of cancer diag-
nosis were eligible for this prospective Institutional
Review Board approved single-center study performed at
the Department of Pediatrics, Masaryk University in Brno,
Czech Republic. Inclusion criteria for patients included:
presence of cancer, serology of EBV and CMV at least at the
time of cancer diagnosis (pre-treatment sample) and 2
months after the end of anticancer therapy (post-treat-
ment sample). Children with cancer undergoing BMT, hu-
man immunodeficiency virus positive children, and
children who died while on anticancer therapy were ex-
cluded from the study. All children were treated according
to approved current protocols for therapy of pediatric ma-
lignancies (Berlin-Frankfurt-Münster protocols for thera-
py of leukemia and non-Hodgkin's lymphoma; Histiocyte
Society protocols for therapy of histiocytoses; Internation-
al Pediatric Oncology Society protocols for treatment of
Hodgkin's disease and solid tumors except for neuroblas-
toma which has been treated according to Pediatric On-
cology Group protocols). As a supportive care,
leukodepleted (containing <105 leukocytes per one trans-
fusion unit) irradiated (50Gy) blood products (packed
red blood cells; platelets obtained by apheresis from one
donor) were given only. Finally, 186 children and adoles-
cents, 101 males and 85 females, met the inclusion crite-
ria; remaining 23 children did not meet that criteria since
they move or their initial or follow-up samples were miss-
ing.
One hundred and sixteen consecutive patients were stud-
ied from 1993 through 1996. In addition, in consecutive
70 patients studied from 1997 through 1999, serology of
HHV-6 at the same time-points as for EBV and CMV, and
monitoring of EBV, CMV and HHV-6 DNA was also per-
formed. If a sample was positive for LH DNA, repeated
samples every 5–7 days were performed until negative.
During anticancer therapy, samples of peripheral blood
for serology and LH DNA study were taken as clinically in-
dicated in the following situations: (1) FN (defined as a
single episode of oral temperature ≥  38.5°C or at least two
episodes of oral temperature ≥  38°C appearing at least 12
hours apart in a patient with absolute neutrophil count ≤
500/ml); (2) fever of unknown origin (FUO) (defined as
oral temperature ≥  37°C lasting for at least 7 days and no
infectious or non-infectious cause of the fever has been
identified); (3) lymphadenopathy, hepatomegaly or
splenomegaly not associated directly with the diagnosis or
relapse of the cancer; (4) liver enzymes (aspartatami-
notransferase or alaninaminotransferase) elevation above
2 standard deviations of normal values; (5) protracted (≥
14 days) bone marrow aplasia (defined as presence of at
least two of the following: leukocytes ≤  1,000/ml, throm-
bocytes ≤  30,000/ml, hemoglobin ≤  80 g/l in peripheral
blood) without the evidence of chemotherapy- or radio-
therapy-induced aplasia; (6) gastroenteritis; (7) atypical
pneumonia; (8) exanthema; and (9) encephalopathy. In-
fection associated with at least one of the symptoms men-
tioned above and confirmed by serology or in
combination with viral DNA detection was designated as
"symptomatic infection".
The population was studied according to cancer diagnosis
(leukemia, lymphoma and solid tumor) and according to
the age at the time of a particular sample has been taken.
Based on age at the time when a pre-treatment sample was
taken, four age groups has been made: 0–1 year old (con-
sisting of 25 children); 2–5 years old (49 children); 6–11
years old (52 children); and 12–17 years old (60 chil-
dren). A total of 218 children 4 months to 17 years old
(31, 54, 62, 71 children in age group 0–1, 2–5, 6–11, 12–
17 years, respectively) and 165 adults 19–78 years old
without infectious or febrile illness who underwent minor
surgery procedure and provided a blood sample for that
purpose, served as a healthy controls for serology testing.
64 children from that group provided samples of periph-
eral blood for LH DNA analysis too. Informed consent hasBMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/1
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been taken from all adults and parents/legal guardians of
all the children.
Serology of LH
All samples were tested by commercially available sets.
ELISA testing kit (DIESSE®, Germany) was used to test the
EBV VCA IgM, EBV VCA IgG, EBV EBNA IgG antibodies
[20] and ELISA testing kit (MEDAC®, Czech Republic) was
used to test the CMV IgM and CMV IgG antibodies in pa-
tient sera [21]. Immunofluorescence assay (IFA) kit
(BAG®, Germany) was used to test the HHV-6 IgM and
HHV-6 IgG antibodies [22]. All tests were performed ac-
cording to manufacturer's instructions. To avoid misinter-
pretation of results, all samples from each patient were
titrated and tested at the same time. The titer results were
expressed semiquantitatively in four grades: negative(-);
mildly positive (+); moderately positive (++); strongly
positive (+++) for each antibody tested.
The presence of EBV VCA IgM positivity (of any grade) fol-
lowed by EBV VCA IgG positivity (of any grade) or in-
creasing EBV VCA IgG positivity with negative EBV EBNA
IgG 14–21 days after an initial level was measured was
considered as a recent primary EBV infection. EBV EBNA
IgG positive (of any grade) case with the presence of the
same pattern of EBV VCA IgM and/or EBV VCA IgG posi-
tivity as in the primary infection was considered as an EBV
reactivation. In case of CMV and HHV-6, the presence of
IgM class antibody positivity (of any grade) followed by
IgG positivity (of any grade), or increasing IgG positivity
14–21 days after an initial level was measured, was con-
sidered as a primary CMV or HHV-6 infection. IgM posi-
tivity (of any grade) in a patient previously IgG positive
was considered as a reactivation of CMV or HHV-6.
DNA analysis of LH
Whole blood samples were collected in K3EDTA tubes
(Sarstedt). Nucleic acids were isolated using silica-based
Nucleic Acids Isolation Kit (Malamite, Czech Republic).
For EBV DNA detection two primer pairs EBER 3 (5' gca
acg gct gct ctg ttt ga), EBER 5 (5' gtg gtc cgc atg ttt tga tc)
and TC60 (5' cca gag gta agt gga ctt), TC61 (5' gac cgg tgc
ctt ctt agg) were used. The lengths of EBER- and TC6-spe-
cific amplification products were 192 bp and 119 bp, re-
spectively. The HCMV DNA was detected using HCMV1
(5' cct agt gtg gat gac cta cgg gcc a) and HCMV2 (5' cag aca
cag tgt cct ccc gct cct c) primers producing 249 bp long am-
plicon and the DNA of HHV6 was amplified with specific
primer pair HP0 (5' ccg caa tcg aat cca cct agc gg) and HP4
(5' gtg aga acg gat tcg aac agt gct g) yielding 440 bp prod-
uct [23,24]. All amplifications were carried out with 20
pmol of each primer in 2 mM solution of MgCl2, 2 U of
Tag Special DNA polymerase (Biovendor, Czech Repub-
lic), 0.3 mM of each dNTPs, 10×  reaction buffer and 1 µg
of isolated DNA according to the following conditions:
96°C for 4 min, (94°C for 10 sec, 58°C for 10 sec, 72°C for
20 sec) 36 times, and final extension at 72°C for 2 min.
The reactions were done in the thermocycler PTC 200 (MJ
Research). The products amplified were run on 3% agar-
ose gel (Lachema, Brno, Czech Republic) and detected by
UV illuminator at 312 nm after staining with ethidium
bromide (5 µg/ml). Electrophoretograms were scanned by
CCD camera (UltraLum) and the relative quantities were
estimated (expressed as follow: (+) = under 100, (++)
from 100 to 10,000, (+++) = more than 10,000 viruses per
105 peripheral leukocytes processed) according the densi-
ties of pathogen-specific bands measured by Scionlmage®
software, using the standard curves of positive controls,
which were derived from 10-fold dilution scales. The set
of "negative control" (1 µl of water instead of isolated
DNA), "negative isolation control" (virus-free blood sam-
ple) and "inhibition controls" (1 µl of each isolate added
in the reaction with 1 µl of positive control DNA) as well
as the "positive control" (only with 1 µl of positive control
DNA = recombinatnt plasmids with inserted amplicons)
was additionaly amplified to reduce the risk of false posi-
tive and/or false negative results. Any positivity detected
by PCR followed by serology results demonstrating recent
LH infection 1 to 5 weeks later was considered as an active
infection.
Statistical analysis
Unconditional logistic regression analysis was performed
with pre-treatment (presence or absence of virus) as the
dichotomous outcome measure. For this analysis group
(patients or controls), age (as a continuous variable), and
the interaction of age and group were the independent
measures. This analysis was repeated for each viral serolo-
gy. To control for age, logistic regressions were performed
within each age group (0–1; 2–5; 6–11; and 12–17) for
each viral serology with group as the only independent
variable. These analyses provide estimates and confidence
intervals of the odds ratios of seroprevalence for pre-treat-
ment cases versus controls adjusting for age. The same set
of analyses was performed with post-transplant cases ver-
sus controls.
To study pre-treatment versus post-treatment patient sam-
ples, a McNemar test was performed for each viral serolo-
gy. McNemar's test determines the degree of agreement
between two paired variables. This test was performed
both overall, ignoring age, and then repeated within each
age group. For the comparison of transfused and non-
transfused patients, chi-square test was used [25].
Results
186 children aged 4 months to 17 years met the inclusion
criteria and were evaluated for the presence of LH infec-
tion during treatment of their cancer. There were 101 boys
and 85 girls 4 months to 17 years old with a mean ageBMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/1
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7.86 years. Post-treatment samples were taken 0.5 to 2.2
years (mean 1.15 years) after pre-treatment ones. Patient
and control characteristics are shown in Table 1.
Serology of LH
Before grouping the ages, a logistic regression analysis was
performed with each viral pre-treatment sample as the di-
chotomous outcome measure and group (patients or con-
trols) as the independent measure with age as a covariate
Table 1: Patient and control characteristics.
Cancer diagnosis Number of patients Mean age and range* Treatment duration – mean and range**
Leukemia group – total 77 6.44 (0.5–16.0) 1.54 (0.7–2.2)
- Acute lymphoblastic leukemia 62
- Acute myeloid leukemia 14
- Myelodysplastic syndrome 1
Lymphoma group – total 42 12.07(2.0–17.8) 0.81 (0.6–1.0)
- Hodgkin's disease 27
- Non-Hodgkin's lymphoma 15
Histiocytosis group – total 9 3.34 (0.3–12.7) 0.72(0.5–1.0)
- Class I. 7
- Class II. 2
Solid tumor group – total 58 7.41 (0.7–17.5) 0.96 (0.5–2.0)
- Brain tumors 21
- Neuroblastoma and PPNET*** 10
- Wilms tumor 7
- Soft tissue sarcoma 7
- Retinoblastoma 5
- Osteosarcoma 5
- Ewing sarcoma 3
Total 186 7.86(0.3–17.5) 1.15 (0.5–2.2)
Controls – pediatric 218 8.21 (0.3–17.3) -
- adult 165 47.53(19–78) -
* Mean age in years at the time of cancer diagnosis; (range). ** Mean interval in years between sample taken at the time of cancer diagnosis and the 
time 2 months after the completion of anti-cancer treatment; (range). *** 8 patients with neuroblastoma (2 patients with stage II., 2 patients with 
stage III. and 4 patients with stage IV.) and 2 patients with PPNET = peripheral primitive neuroectodermal tumor.
Table 2: Unconditional logistic regression analysis for age groups.
Virus Age group Pre-treatment Post-treatment
p-value OR odds CI p-value OR CI
EBV 0–1 0.89 1.09 0.27–4.39 0.0008 0.1 0.03–0.39
2–5 0.73 1.15 0.52–2.54 0.0118 0.29 0.11–0.76
6–11 0.64 1.23 0.51–2.98 0.29 0.58 0.21–1.60
12–17 0.36 1.57 0.60–4.17 0.81 0.87 0.29–2.60
CMV 0–1 0.4 1.78 0.47–6.79 0.0413 0.36 0.11–0.96
2–5 0.65 1.19 0.55–2.61 0.0020 0.28 0.12–0.63
6–11 0.57 1.24 0.59–2.59 0.0042 0.33 0.16–0.71
12–17 0.71 1.14 0.57–2.26 0.0272 0.45 0.22–0.91
HHV-
6
0–1 0.0471 3.36 1.02–11.1 0.53 0.65 0.17–2.51
2–5 0.0071 5.07 1.55–16.5 0.68 1.33 0.34–5.25
6–11 0.64 1.34 0.39–4.67 0.54 0.63 0.14–2.78
12–17 0.92 1.07 0.27–4.16 0.43 0.51 0.10–2.75BMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/1
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and including the age by group interaction term. There
was no statistically significant difference in overall serop-
ositivity between patients and controls for EBV VCA IgG
(68.8% vs. 72.0%; p = 0.47) and CMV IgG (37.6% vs.
41.7%; p = 0.36) pre-transplant samples. There was a sta-
tistically significant difference in the age measure showing
that the number of EBV and CMV IgG seropositive cases
in pre-treatment samples increases with age (p < 0.0001;
resp. p = 0.0131). The interaction of age and group meas-
ure was not significant (p = 0.23 for EBV and p = 0.60 for
CMV). Overall pre-treatment IgG seropositivity for HHV-
6 was significantly lower in patients than in controls
(80.6% vs. 91.3%; p = 0.0231). The age measure was also
significantly different (p < 0.0001) demonstrating increas-
ing HHV-6 IgG positivity with age. The interaction of age
and group measure for HHV-6 was not significant (p =
0.07).
For each age group and each virus, a logistic regression
analysis was performed with pre-treatment sample as the
dichotomous outcome measure and group (patients or
controls) as the independent outcome measure. There
were no statistically significant differences between pre-
treatment patient samples and controls in all age groups
for EBV VCA IgG, CMV IgG and in the 6–11 and 12–17
age groups for HHV-6 IgG. The only differences were no-
ticed for HHV-6 in the 0–1 and 2–5 age groups where pa-
tients had lower IgG seropositivity then the controls.
Statistical data including p-values, odds ratios and odds
confidence intervals are summarized in Table 2.
The same analyses were performed with post-treatment
patient samples and controls. There was increased overall
post-treatment seropositivity that was significantly differ-
ent from controls for EBV VCA IgG (86.6% vs. 72.0%; p =
0.0004) and CMV IgG (67.7% vs. 41.7%; p < 0.0001). No
difference in the age measure was found demonstrating
that the number of EBV and CMV seropositive cases in
post-treatment samples does not increase with age (p =
0.87; resp. p = 0.62). In case of HHV-6 IgG, no difference
was found between post-treatment samples and controls
(94.3% vs. 91.3%; p = 0.58). The age measure was signif-
icantly different (p = 0.0355) demostrating increasing
HHV-6 IgG seropositivity with age. There was no signifi-
cant difference in the interaction of age and group meas-
ure for EBV, CMV and HHV-6, respectively (p = 0.73; p =
0.57; resp. p = 0.07).
For each age group and each virus, a logistic regression
analysis was performed with post-treatment sample as the
dichotomous variable and group (patients or controls) as
the independent variable. There were statistically signifi-
cant differences between post-treatment patient samples
and controls in the 0–1 and 2–5 age groups for EBV VCA
IgG and in all age groups for CMV IgG demonstrating
higher seropositivity in patients than in controls. No dif-
ferences were noticed in the 6–11 and 12–17 age groups
for EBV VCA IgG and in all age groups for HHV-6 IgG. Sta-
tistical data including p-values, odds ratios and odds con-
fidence intervals are summarized in Table 2. Figure 1
demonstrates LH IgG seropositivity in patient pre- and
post-treatment samples and in controls.
To compare pre-treatment and post-treatment samples, a
McNemar test was performed for each viral serology. This
test was performed both overall, ignoring age, and then re-
peated within each age group. Overall McNemar test dem-
onstrated statistically significant difference between pre-
and post-treatment patient samples for all three LH (p <
0.0001). There were also statistically significant differenc-
es in all age groups for EBV (age group 0–1: p = 0.0016;
age group 2–5: p = 0.0003; age group 6–11: p = 0.0143;
and age group 12–17: p = 0.0455), in all age groups for
CMV (age group 0–1: 0.0082; age group 2–5: p < 0.0001;
age group 6–11: p < 0.0001; and age group 12–17: p =
0.0003) and in two age groups for HHV-6 (age group 0–
1: p = 0.0082; age group 2–5: 0.0016). No significant dif-
ference was found in the age group 6–11 (p = 0.08) and
12–17 (p = 0.15) for HHV-6. The data are summarized in
Figure 1.
Using the McNemar test, we compared IgG seropositivity
between pre-treatment and post-treatment samples ac-
cording to cancer diagnosis described in Table 1, i.e.
leukemias, lymphomas and solid tumors (the group of
histiocytosis was not analyzed this way since the number
of subjects was too small for statistical analysis). EBV VCA
IgG, CMV IgG and HHV-6 IgG seropositivity, respectively,
was significantly different in the leukemia group (p =
0.0004; p < 0.0001; resp. p = 0.0245). There was also a sta-
tistically significant difference for CMV IgG in the lym-
phoma and solid tumor groups (p = 0.0058; resp. p =
0.0008). No statistically significant difference was noticed
for EBV VCA IgG and HHV-6 IgG in the lymphoma (p =
0.36; resp. p = 0.75) and solid tumor (p = 0.25; resp. p =
0.12) groups. The data are summarized in Figure 2.
Based on serology, we were able to demonstrate the rate
of primary infection and reactivation of LH in most of the
patients during anticancer treatment. The results are
shown in Figure 3. Primary infection with EBV and CMV
occurs in almost 50% of children less than 6 years of age.
Primary HHV-6 infection is less frequent. In older chil-
dren, EBV and HHV-6 reactivation also occurs. We were
able to distinguish primary infection from reactivation in
all cases of symptomatic EBV infection based on EBNA
IgG status. In case of CMV and HHV-6 there were 4 and 2
cases, respectively, where it was impossible to distinguish
that. In addition, two of that cases showed CMV and
HHV-6 crossreactivity.BMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/1
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Figure 1
LH serology according to the age. # (p < 0.05), ## (p < 0.01) statistically significant difference between a group of patients at the
time of cancer diagnosis (Pre-Tx) and 2 months after the end of anticancer treatment (Post-Tx). * (p < 0.05), ** (p < 0.01) sta-
tistically significant difference between a group of patients and a group of age-matched healthy controls.BMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/1
Page 7 of 11
(page number not for citation purposes)
Figure 2
LH serology according to the diagnosis. # (p < 0.05), ##(p < 0.01) statistically significant difference between a group of patients
at the time of cancer diagnosis (Pre-Tx) and 2 months after the end of anticancer treatment (Post-Tx).BMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/1
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Figure 3
Primary infection and reactivation of LH. Percentage of seropositive cases (EBV VCA IgG; CMV IgG; HHV-6 IgG) in each age
group (0–1, 2–5, 6–11 and 12–17 years old).
Table 3: Comparison of LH detection. EBV and CMV infections were studied in 1993–96 by serology only in 116 patients. In 1997–99 the 
combination of serology and DNA analysis of EBV, CMV and HHV-6 were performed in 70 patients. Percentage of positive cases is 
shown for each virus.
EBV CMV HHV-6
Symptomatic infection [%] detected by
- serology only (1993–96) (n = 116) 13.8 6.0 -
- serology + DNA (1997–99) (n = 70) 30.0 20.0 18.6
Laboratory infection [%] detected by
- serology only (1993–96) (n = 116) 33.6 34.5 -
- serology + DNA (1997–99) (n = 70) 37.1 38.6 32.9BMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/1
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Analysis of LH DNA and comparison with LH serology
We examined 215 blood samples from 70 patients. Sixty
four healthy individuals served as controls. Seventeen
(24%), 18 (26%), and 21 (30%) patients were PCR EBV,
CMV and HHV-6, respectively, (+) to (+++) positive. In
comparison, 2 (3%), 1 (2%), and 5 (8%) healthy controls
were PCR EBV, CMV and HHV-6, respectively, (+) posi-
tive; none was (++) or (+++) positive. All cases of PCR
(++) or (+++) positive results obtained from 10, 8, and 13
patients with EBV, CMV and HHV-6 active symptomatic
infection, respectively, corresponded with serological
findings of recent infection occurring 1–5 weeks follow-
ing the first PCR positive result. In case of PCR EBV, CMV
and HHV-6 (+) positive result, the serology finding of re-
cent infection corresponded in 7/7, 6/10 and 3/8 patients,
respectively. Four and 5 patients were PCR CMV and
HHV-6 (+) positive, respectively, but lacking serological
evidence of recent infection. Since they had symptomatic
infection, we considered them being infected with a par-
ticular virus and all of them showed serological evidence
of previous infection in post-treatment samples. Besides
that, there were 4 patients PCR EBV negative who demon-
strated recent infection by serology. One patient had coin-
fection of EBV and HHV-6 during anticancer treatment
detected by PCR [EBV (+++) positive, HHV-6 (+)] with se-
rological evidence of primary EBV infection and reactiva-
tion of HHV-6.
Data summarized in Table 3 provide the information
about the differences in diagnosis of EBV and CMV infec-
tion. By combination of serology and DNA analysis, we
were able to detect symptomatic infection more frequent-
ly in comparison to serology only (p = 0.013 for EBV; p =
0.007 for CMV). As expected, the rates of "laboratory in-
fection", defined as the sum of the cases with symptomat-
ic infection and positive seroconversion for each virus,
were not significantly different in these two groups. Labo-
ratory EBV and CMV infection was present in 65 (34.9%)
and 66 (35.4%) of 186 patients, respectively. Laboratory
HHV-6 infection was present in 23 (32.9%) of 70 pa-
tients.
The influence of blood products on LH infection
One hundred fifty six children (83.9%) were given at least
one blood product transfusion during treatment. Fifty
four (34.6%) and 57 (36.5%) children out of 156 trans-
fused children were infected with EBV and CMV, respec-
tively. Eleven (36.7%) and 9 (30.0%) children out of 30
non-transfused children were infected with EBV and CMV,
respectively. In addition, eighteen (29.5%) out of 61 chil-
dren transfused in the period from 1997 through 1999
were infected with HHV-6 while 5 (55.6%) children out
of 9 non-transfused children were infected with HHV-6.
There was no statistically significant difference in the inci-
dence of EBV (p = 0.64), CMV (p = 0.16) or HHV-6 (p =
0.24) infection in between transfused and non-transfused
patients.
Discussion
Frequent infection with herpesviruses has long been rec-
ognized in patients undergoing allogeneic transplantation
[7,8] and in patients with acute leukemia [1,2]. In patients
with acute leukemia it has been reported that as many as
two thirds of seropositive patients can develop reactiva-
tion of herpes simplex virus infection during remission in-
duction therapy [26]. The risk of CMV infection in acute
leukemia patients was recognized almost 30 years ago
[27] but is of particular concern in patients undergoing al-
logeneic transplantation [2,28]. EBV infection is frequent-
ly associated with post-transplantation
lymphoproliferative disorders in T cell-depleted grafts
[29]. As recently reported, HHV-6 can also be associated
with bone marrow supression [30], encephalitis and
pneumonitis [7,8] after allogeneic transplantation.
Whether symptomatic LH infection occurs in chemother-
apy- and/or radiotherapy-treated cancer patients has not
been reported. This report demonstrates for the first time
that LH infection affects more than one third of children
treated for cancer. EBV and CMV infection occurred in al-
most 50% of children younger then 6 years during anti-
cancer treatment. At the time of cancer diagnosis the rate
of EBV and CMV seropositivity was not different in cancer
patients and healthy controls. On the other hand, chil-
dren in all age groups reached similar EBV and CMV sero-
positivity levels after anticancer treatment comparing to
healthy adult controls. It suggests that children immuno-
supressed by chemotherapy and/or radiotherapy have
high incidence of LH infection. As expected, primary in-
fection was the most frequent in younger patients and re-
activation occurred in older patients. In case of HHV-6
infection, which affects most of humans by the age of 2
years, we were surprised with low frequency of IgG anti-
bodies in pre-treatment samples as compared with age-
matched healthy controls. There might be at least two pos-
sible mechanisms involved. First, due to either lower sen-
sitivity to detect HHV-6 IgG antibodies by IFA or due to
immune supression at the time of cancer diagnosis but
similar pattern was not seen for EBV or CMV. Second, due
to the possibility that prior infection with HHV-6 might
be directly or indirectly protective against tumor develop-
ment. This finding would be in agreement with Greaves
hypothesis [31,32] which predicted an increased risk of B-
cell precursor ALL for those of higher socioeconomic lev-
el, firstborn children, and those with delayed or dimin-
ished exposure to common infections in infancy. When
we studied our patient population based on cancer diag-
nosis, the only statistically significant difference between
pre- and post-treatment samples was noticed in patients
with leukemia (p = 0.0245) but not in patients with lym-BMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/1
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phoma or solid cancer (Figure 2). To our knowledge, there
are no other data in the literature describing a protective
effect of HHV-6 infection in infancy against leukemia.
Further studies would be needed to test this association.
As previously demonstrated, the risk of transfusion-ac-
quired CMV infection can be significantly reduced by the
use of CMV-seronegative or filtered (white blood cell re-
duced) blood products [33]. In an effort to illustrate the
role of leukodepleted blood transfusions in transmission
of LH infection in pediatric oncology patients we studied
both populations: a population of patients treated with
leukodepleted irradiated blood products and a popula-
tion of patients that did not required any blood transfu-
sion during anticancer treatment. No statistically
significant difference for each LH virus was found in these
two groups. Those data are in accordance with recently
published prospective study by Preiksaikis et al. [34]
where the risk of transfusion-acquired CMV infection was
estimated to be less than 1 in 698 donor exposures in chil-
dren with cancer.
In the literature describing LH detection by PCR, the re-
sults vary widely since different protocols have been used
in different biological materials [7–10,14]. PCR method
was used in patients undergoing BMT or organ transplants
but not in chemotherapy-only and/or radiotherapy-only
treated patients. To our knowledge, this report demon-
strates for the first time a correlation of serological results
with viral load detected by PCR in children with different
types of cancer. By using healthy controls and setting the
threshold of PCR positive versus negative based on corre-
lation with clinical symptoms and serology, acute LH in-
fection could be identified in most of the cases. The
highest incidence of LH infection occurred among pa-
tients with leukemia. It probably corresponds with the
length of neutropenia and severity of immunosupression
that is greater in patients treated for leukemia compared
to patients with lymphoma or solid tumor.
Conclusion
This paper demonstrates that EBV, CMV and HHV-6 infec-
tion is frequent in children treated for cancer, is not trans-
fusion-dependant, and is often associated with clinical
symptoms. Combination of serology and PCR method in
detection of symptomatic disease is superior to serology
alone. Further studies are needed to identify patients at
higher risk of severe LH infection to prevent disease-asso-
ciated morbidity and to test the hypothesis that HHV-6 in-
fection early in the infancy may be protective against
leukemia in the frame of Greaves hypothesis.
Abbreviations
FN febrile neutropenia
LH lymphotropic herpesviruses
EBV Epstein-Barr virus
CMV cytomegalovirus
HHV-6 human herpesvirus 6
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